Austar Lifesciences Limited released its 2025 Environmental, Social and Governance Report, detailing progress in decarbonisation, resource efficiency and stakeholder management across its operations in Mainland China and Hong Kong.
Double-digit cuts in key pollutants • Scope 1 carbon emissions rose to 93.57 tCO₂e, but stronger renewable sourcing enabled Scope 2 market-based emissions to fall 6.48 % year on year to 2,099.46 tCO₂e. Total market-based emissions declined 11.69 % to 2,797.27 tCO₂e. • Renewable electricity consumption increased 45.93 % to 628.62 MWh after solar panels were added at the Shanghai facility, lifting green power’s share of total electricity use to 17.30 %. • Hazardous waste fell 48.93 % to 1.67 tonnes, while non-hazardous waste dropped 49.57 % to 79.95 tonnes.
Resource-efficiency indicators • Total energy use was broadly stable at 4,753.75 MWh; energy intensity improved to 3.11 MWh per million RMB of revenue. • Water consumption reached 41,280 m³, with intensity at 26.97 m³ per million RMB. • Packaging material usage declined to 282.30 tonnes, down 22.07 % from 2024.
Long-term climate target The Board approved a goal to cut Scope 1 and 2 GHG intensity (per revenue) by 3 % by 2035 from a 2024 baseline, supported by expanded on-site renewables, energy-efficient equipment upgrades and increased waste-heat recovery.
Governance structure strengthened The Board retains ultimate ESG oversight, supported by an executive committee spanning production, procurement, finance, HR and legal. Climate risk assessment aligned with SSP1-2.6 and SSP5-8.5 scenarios was completed with third-party advisers; assets representing ≥5 % of total value exposed to “very high” climate risk trigger escalation.
External validation and customer focus • Subsidiary Austar Hansen Lifesciences earned an EcoVadis “Committed” badge in its inaugural sustainability assessment. • Customer satisfaction averaged 97 %, with zero product recalls or significant complaints recorded in 2025.
People and supply-chain highlights • Headcount totalled 1,468, of which 52.0 % were male; voluntary turnover fell to 10.57 %. Employees completed 16,024 training hours, covering 89.2 % of staff. • Supplier base stood at 1,709, 98 % of which are in Mainland China; all must sign a Corporate Social Responsibility Commitment and complete ESG self-assessments.
Compliance record The company reported no material breaches of environmental, labour, health-and-safety or anti-corruption regulations during the year.
Strategic repositioning Early 2025 saw AUSTAR sharpen its identity from “pharmaceutical engineering solution provider” to “Better Technology, Better Life Sciences”, signalling deeper focus on life-science process technologies and digital energy-management solutions.
Cost savings via green engineering A flagship waste-heat recovery project for a veterinary-pharmaceutical client converted 260 tonnes of hot-water effluent daily into heating, saving an estimated RMB 0.76 million annually with a one-to-two-year payback.
The Board approved the ESG report on 26 March 2026, reaffirming AUSTAR’s commitment to embed sustainability across its value chain while pursuing measured growth in the life-sciences sector.
Comments